Patent application number | Description | Published |
20090122755 | DATA TRANSMISSION METHOD IN WIRELESS MESH NETWORK AND A-MSDU FORMAT - Provided are a method for transmitting data in wireless mesh networks and A-MSDU format for the method. In the method, in case the receiving MPs of all of the plural MSDUs to be transmitted are identical, a transmitting MP generates an A-MSDU using the plural MSDUs and transmits the A-MSDU to the receiving MP. The A-MSDU includes a plurality of A-MSDU sub-frames each of which includes a sub-frame header unit, an MSDU unit for containing data of each of the plural MSDU, and a padding unit for making each A-MSDU sub-frame a multiple of 4 octets in length. The sub-frame header unit comprises a mesh DA field for specifying an MAC address of the destination MP of the data contained in the MSDU unit, a mesh SA field for specifying an MAC address of the source MP of the data contained in the MSDU unit, and a mesh header field for containing information of the mesh header of each of the plural MSDUs. | 05-14-2009 |
20090122774 | MESH DETERMINISTIC ACCESS (MDA) PROCEDURE IN WIRELESS MESH NETWORK AND WIRELESS DEVICE SUPPORTING THE SAME - Provided are a procedure for mesh deterministic access (MDA) in wireless mesh network and a wireless device supporting the procedure. In the method, an intended transmitter transmits an a mesh deterministic access opportunity (MDAOP) setup request message including information for specifying times of a new MDAOP set and information for identifying the new MDAOP set to intended receivers. In this case, the MDAOP setup request message is a setup request message for a broadcast MDAOP. And, the intended transmitter receives an MDAOP setup reply message including a reply code from the intended receivers. The reply code may indicate either accept or refusal of the request for the new MDAOP set. | 05-14-2009 |
20100278166 | METHOD FOR SWITCHING CHANNEL IN MESH NETWORK - A method of performing a channel switch in a mesh network by a first Mesh Point (MP) includes configuring a peer link between the first MP and a second MP, and transmitting a mesh channel switch announcement frame from the first MP to the second MP. The mesh channel switch announcement frame includes a new regulatory class field and a new channel number field. The new regulatory class field indicates the number of a new regulatory class after the channel switch and the new channel number field indicates the number of a new channel to which the first MP is moving. | 11-04-2010 |
20110019686 | PATH SELECTION PROCEDURE IN MESH NETWORK AND FORMAT OF PATH REQUEST FRAME THEREFOR - A method for selecting a transmission path from a source mesh point (MP) to a destination MP in a mesh network is provided. The source MP broadcasts a frame comprising a path request (PREQ) element. According to a power management state of an intermediate MP that receives the frame, the PREQ element comprises power management mode consideration information for controlling forwarding the received PREQ element for the destination MP. A transmission delay due to delay of data requested to be transmitted in real time at the MP operating in the PSM can be prevented. | 01-27-2011 |
Patent application number | Description | Published |
20100098700 | PHARMACEUTICAL COMPOSITIONS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to compositions that comprise an anti-S1P monoclonal antibody, antibody fragment, or derivative in a carrier, particularly a buffered, hypertonic aqueous solution, as well as to kits containing such compositions, and methods for using such compositions for treatment of diseases and conditions associated with S1P. | 04-22-2010 |
20130058951 | ANTI-S1P ANTIBODY TREATMENT OF PATIENTS WITH OCULAR DISEASE - The present invention relates to methods that involve administration of an anti-S1 P antibody or antibody fragment or derivative to a subject having or suspected of having an ocular disease or condition, including one involving choroidal neovascularization, in order to achieve a desired effect. Such effects include reducing the size of a choroidal neovascularization lesion in the eye, decreasing or resolving retinal pigment epithelial detachment, decreasing central retinal lesion thickness, and preserving or improving visual acuity. Pharmaceutical compositions comprising an anti-S1 P antibody for ocular administration are also provided. The compositions and methods are particularly useful for treating subjects having age-related macular degeneration, particularly exudative or wet age-related macular degeneration. | 03-07-2013 |